An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer

Completed

• Conditions: Pancreatic Cancer; Neoadjuvant
• Interventions: Drug: Neoadjuvant treatment

• Registration Number: NCT06129812
• Lead Sponsor: Seoul National University Hospital

Brief Summary

An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer

Detailed Description

The 1,132 patients with resectable or borderline resectable PDAC who underwent surgery between 2007 and 2021 were retrospectively reviewed. Patients with resectable PDAC without contact of major vessels (R-no contact) (n=651), with contact of portal vein or superior mesenteric vein (PV/SMV) ≤180° (R-contact) (n=306), and borderline resectable PDAC without arterial involvement (BR-V) (n=175) were analyzed.

Study Timeline

• Study Start: 2007-01
• Primary Completion: 2021-12
• Study Completion: 2021-12
• Status Verified: 2023-09
• Study First Submitted: 2023-10-27
• Study First Submitted QC: 2023-11-09
• Last Update Submitted: 2023-11-09
• Study First Posted: 2023-11-13
• Last Update Posted: 2023-11-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1132

Inclusion Criteria

• Patients diagnosed with resectable or borderline resectable pancreatic ductal adenocarcinoma (PDAC)
• Between January 2007 and June 2021 at Seoul National University Hospital

Exclusion Criteria

• Patients who had borderline resectable PDAC with arterial invasion
• Patients who received chemotherapy as initial treatment and did not undergo surgery
• Incomplete follow-up data for analysis

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
resectable PDAC with contact PV/SMV of ≤180° (R-contact)	Neoadjuvant treatment	-
resectable PDAC with no contact to major vessels (R-no contact)	Neoadjuvant treatment	-
borderline resectable PDAC with PV/SMV contact >180° and without arterial involvement (BR-V)	Neoadjuvant treatment	-

Primary Outcome Measures

Name	Time	Method
Overall survival	From the date when biopsy results came out until the date of death from any cause or the date of the last visit, whichever came first, assessed up to 60 months	the time from diagnosis to death from any cause or the date of the last visit